Publications by authors named "Naoto Yoshinari"
Background: A recent meta-analysis has found that patients who have achieved remission of major depressive disorder (MDD) show cognitive dysfunction. Moreover, anticholinergic activity levels are associated with cognitive dysfunction, although the extent of these effects is unclear. Therefore, we measured serum anticholinergic activity (SAA) in blood samples of patients with remitted MDD and examined its relationship with cognitive function.
View Article and Find Full Text PDFPatients with bipolar disorder often report self-perceived treatment resistance. However, it is not known to what extent it is due to actual treatment resistance. The Juntendo University provides "Bipolar Disorder Treatment Rebuilding Program," in which patients with self-reported treatment resistant bipolar disorder are hospitalized for 2 weeks and undergo detailed examinations.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates whether serum levels of brain-derived neurotrophic factor (BDNF) in people with depression can predict the future onset of dementia.
- It measured BDNF levels in individuals both during acute depression and after they had remitted from it, tracking them for a mean period of 24.3 months.
- The results showed that lower BDNF levels after depression remission were associated with a higher risk of progressing to dementia or mild cognitive impairment, indicating a possible link between BDNF and the transition from depression to dementia.
Article Synopsis
- Depression may increase the risk of Alzheimer's disease by affecting amyloid β (Aβ) metabolism, prompting this study to investigate how Aβ levels change over time after depression.
- During the study of 277 elderly patients with depression, it was found that they had lower Aβ42 levels and higher Aβ42/40 ratios at the onset of depression, but these levels normalized only one year after remission.
- The findings suggest that managing depression over a longer term can help mitigate Alzheimer's-related changes in the brain, but results may be influenced by the use of antidepressants.
Article Synopsis
- The study investigates the relationship between the ε4 allele of the apolipoprotein E gene (APOE4) and the recurrence of depression in patients diagnosed with major depressive disorder (MDD) after achieving remission.
- It followed 163 patients, comparing APOE4 carriers and non-carriers, finding that carriers had a significantly higher likelihood of experiencing subsequent depression recurrences.
- Limitations include variations in antidepressant treatments among participants, a mix of first-time and recurrent depression episodes, and insufficient data to analyze different genetic variants of APOE4 on recurrence risk.